Main Menu

Heartland virus (HRTV) is a novel tick-borne virus first discovered in 2009 that causes flu-like symptoms such as fever, headaches, fatigue, muscle aches, and diarrhea. Patients with HRTV often have low white blood cell counts, low platelet counts, and abnormal liver function tests which can become severe. Cases of Heartland virus disease have been identified in the Midwestern and southern United States. There are no vaccines to prevent or medications to treat Heartland virus infections.

The Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Resulting infection by this virus can cause early miscarriage and a pattern of severe birth defects in fetuses and infants. Therefore, a rapid diagnostic assay that can be performed throughout pregnancy in a clinical setting is vital for prenatal care of women living in areas where this virus may be transmitted.

Antibiotic resistance is one of the world's most pressing health concerns. ß-lactamases, such as carbapenemases, are enzymes produced by bacteria that provide resistance to multiple ß-lactam antibiotics (e.g., penicillins, cephamycins, and carbapenems) by breaking down the antibiotic molecules and deactivating their antibacterial properties. Carbapenems are broad-spectrum antibiotics often prescribed to treat serious infections in hospitalized patients, and infections with carbapenem-resistant Enterobacteriaceae (CRE) have become a challenge in healthcare settings.

Rabies occurs in more than 150 countries and territories, resulting in at least 55,000 human deaths per year worldwide according to World Health Organization estimates. Rabies is a vaccine-preventable viral disease caused by numerous lyssaviruses that are found in a variety of animal species throughout the world. Rabies virus infects the central nervous system, causing disease in the brain with almost 100% mortality once clinical symptoms manifest.

Currently available identification methods for antigen-specific antibodies require live pathogens, antisera (that are only available for a limited number of species), and species-specific secondary antibodies (also a limited resource). Thus, detection or surveillance of pathogens in wild avian species or zoo animals, for example, is complex and cumbersome.

CDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. This technology describes an identified CD4+ T cell epitope occurring within the E-glycoprotein of West Nile virus and methods of using this polypeptide to increase vaccine immunogenicity in monovalent vaccines.

CDC researchers have identified and characterized discrete flavivirus cross-reactive epitopes useful for improving serodiagnosis and vaccination of flaviviruses, such as dengue virus, yellow fever virus, Japanese encephalitis virus, West Nile virus and the tick-borne encephalitis viruses.

CDC researchers have developed a bead-based nucleic acid assay for serotyping members of the Salmonella genus; this assay will identify serotypes for approximately 95% of all human-obtained Salmonella isolates in the United States.

This CDC-developed technology entails novel compositions and methods related to the diagnosis of Lyme disease. Lyme disease, caused by the Borrelia burgdorferi bacterium, is the most common tick-borne infectious disease in the US and Europe. Diagnosis of Lyme disease is particularly challenging as symptoms often appear long after exposure. At present, the only FDA-approved diagnostic for Lyme disease involves patient blood tests for particular antibodies; these include an ELISA to measure patient antibody levels and a Western blot assay to detect antibodies specific to B.

This CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal illness in hosts.